Generation Bio Co 's ability to collect its outstanding accounts receivable from its corporate clients, has improved in the third quarter 2025 to a ratio of 18.72, above the company average. This is a clear sign of healthy business climate in the Major Pharmaceutical Preparations industry and improving liquidity at their respective customers, during the third quarter 2025. Average receivable collection period, for the Generation Bio Co in Sep 30 2025 quarter, has decreased to 19 days, compared to 22 days, in the Jun 30 2025 quarter.

If we take a look into Healthcare sector 464 other companies have achieved higher receivables turnover ratio. While total ranking has deteriorated relative to the period ending Sep 30 2025 from 2743 to 3059.

What is Receivable Turnover Ratio?
What is Generation Bio Co Selling?

What is Receivable Turnover Ratio?

Select the Comparisons :

None ▼

Select the Ratio:

Accounts Receivables Turnover▼

None ▼

Accounts Receivables Turnover▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

GBIO Receivables Turnover Ratio	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter	(Mar 31 2025) I. Quarter	(Dec 31 2024) IV. Quarter	(Sep 30 2024) III. Quarter
Y / Y Receivable Change	-82.32 %	-80.85 %	-	-69.09 %	235.15 %
Y / Y Revenue Change	-78.9 %	-81.3 %	114.91 %	45.52 %	252 %
Receivable Turnover Ratio (TTM)	18.72	16.7	15.93	16.67	9.9
GBIO's Total Ranking	# 3059	# 2743	# 2975	# 2838	# 2325
Accounts Receivable average collection period days	19	22	23	22	37
Seq. Receivable Change	52.73 %	-81.61 %	13.73 %	-44.67 %	65.45 %
Seq. Revenue Change	108.37 %	-91.23 %	108.29 %	-44.56 %	84.65 %

Receivable Turnover Company Ranking
Within:	No.
Major Pharmaceutical Preparations Industry	# 159
Healthcare Sector	# 465
Overall Market	# 3059

Receivable Turnover Ratio Statistics
High	Average	Low
0.1	0.07	0.03
(Mar 31 2025)		(Mar 31 2024)

GBIO Company Profile • Back to GBIO Efficiency Comparisons • Compare GBIO Receivables Turnover Ratio to its Competitors

Financial Statements
Generation Bio Co 's Accounts Receivable	$ 0 Millions	Visit GBIO's Balance sheet
Generation Bio Co 's Sales TTM	$ 15 Millions	Visit GBIO's Income Statement
Sources of GBIO's Revenues		Visit GBIO's Sales by Geography

Other Accounts Receivable Turnover Ratios
Major Pharmaceutical Preparations Industry Accounts Receivable Turnover Trends and Statistics
Healthcare Sector Accounts Receivable Turnover Statistics
Accounts Receivables Turnover Trends for overall market
GBIO's Receivable Turnover Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Accounts Receivables Turnover
Lowest Ranking Accounts Receivables Turnover

You may also want to know
GBIO's Growth Rates	GBIO's Roa	GBIO's Inventory Turnover Ratio	GBIO's Dividend Comparisons
GBIO's Profitability Ratios	GBIO's Roi	GBIO's Asset Turnover Ratio	GBIO's Dividend Growth
GBIO's Valuation Ratios	GBIO's Roe	GBIO's Financial Strength Ratios	GBIO's Dividend Payout Ratio

Companies with similar Receivables Turnover Ratio for the quarter ending Sep 30 2025, within Healthcare Sector	Receivable Turnover Ratio	Revenues for 12 Months ending Sep 30 2025	Receivable at quarter ending Sep 30 2025
Logicmark Inc	107.06	$ 10.609 Millions	$ 0.099 Millions
Aclaris Therapeutics Inc	82.63	$ 15.741 Millions	$ 0.191 Millions
Monte Rosa Therapeutics Inc	81.44	$ 181.538 Millions	$ 2.229 Millions
Longduoduo Co Ltd	73.11	$ 4.152 Millions	$ 0.057 Millions
Sbc Medical Group Holdings Incorporated	71.44	$ 176.776 Millions	$ 2.474 Millions
Atara Biotherapeutics Inc	69.93	$ 214.503 Millions	$ 3.068 Millions
Eyepoint Inc	62.29	$ 42.340 Millions	$ 0.680 Millions
Stoke Therapeutics Inc	59.76	$ 205.632 Millions	$ 3.441 Millions
Agenus Inc	55.26	$ 106.829 Millions	$ 1.933 Millions
Brookdale Senior Living Inc	55.20	$ 3,220.921 Millions	$ 58.351 Millions
Airsculpt Technologies Inc	53.94	$ 157.554 Millions	$ 2.921 Millions
Cytomx Therapeutics Inc	53.12	$ 113.631 Millions	$ 2.139 Millions
Lifevantage Corp	50.18	$ 227.759 Millions	$ 4.539 Millions
Humacyte Inc	46.85	$ 22.958 Millions	$ 0.490 Millions
Agape Atp Corporation	45.47	$ 1.485 Millions	$ 0.033 Millions
Fortrea Holdings Inc	45.15	$ 2,759.900 Millions	$ 61.125 Millions
Silence Therapeutics Plc	38.75	$ 25.830 Millions	$ 0.667 Millions
Nature s Sunshine Products inc	38.67	$ 474.009 Millions	$ 12.258 Millions
National Vision Holdings Inc	38.15	$ 1,861.626 Millions	$ 48.800 Millions
X4 Pharmaceuticals Inc	37.60	$ 33.979 Millions	$ 0.904 Millions
Kyntra Bio Inc	37.51	$ 8.298 Millions	$ 0.221 Millions
Orchestra Biomed Holdings Inc	35.67	$ 2.818 Millions	$ 0.079 Millions
Lineage Cell Therapeutics Inc	35.06	$ 10.816 Millions	$ 0.309 Millions
Wave Life Sciences Ltd	33.51	$ 109.230 Millions	$ 3.260 Millions
Lipocine Inc	32.23	$ 4.323 Millions	$ 0.134 Millions
Invo Fertility Inc	32.11	$ 6.944 Millions	$ 0.216 Millions
Metagenomi Therapeutics Inc	30.14	$ 30.913 Millions	$ 1.025 Millions
Longeveron Inc	29.33	$ 1.437 Millions	$ 0.049 Millions
U S Physical Therapy Inc	29.22	$ 758.711 Millions	$ 25.966 Millions
Lifemd Inc	28.68	$ 250.860 Millions	$ 8.746 Millions

Date modified: 2026-09-08T15:22:15+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.